China Medical (CMED) Receives Chinese Approval For Its Bladder Cancer FISH Probe
More News related to CMED
- China Medical Tech (CMED) Receives SFDA Approval for Leukemia Fusion Detection FISH Probe
- China Medical Technologies Receives SFDA Approval for its Leukemia BCR/ABL Fusion Gene Detection FISH Probe
- China Medical Technologies to Announce Unaudited Financial Results for the Second Fiscal Quarter Ended September 30, 2009 on November 19, 2009
- Don't Miss Out! The Registration Period for the 2010 IR Global Rankings Ends TOMORROW!
- Time Is Running Out to Have Your IR Program Independently Evaluated!
More News related to FDA
- Novartis (NVS) Acquires Majority Stake in Zhejiang Tianyuan Bio-Pharmaceutical for $125 Million
- Ford (F) Gets $2.81B in Net Proceeds from Notes Offering
- Fed says fewer banks reported tightening credit in Q3
- Highlights From Energy Conversion Devices' (ENER) Q1 Conference Call; Continue To Face Challenging Market Environment
- Verizon Claims Strong Sales of Motorola's New 'Droid', But Won't Give Specific Numbers (VZ, MOT)
China Medical Technologies, Inc. (Nasdaq: CMED) has received approval for its Bladder Cancer FISH Probe (the "Probe") from the State Food and Drug Administration (the "SFDA") in the People's Republic of China.
The Probe is an advanced molecular diagnostic test kit that uses DNA probes for early detection and monitoring the course of bladder cancer. It is designed to detect and identify whether aneuploidy for chromosomes 3, 7, 17 and loss of the p16 locus are present in the human bladder cells. [SM]
Related Categories
FDAStocks Mentioned
+0.14Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
